Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biora Therapeutics Inc

Biora Therapeutics, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include the Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biora Therapeutics excels in therapeutics programs, secures strategic partnerships

Biora Therapeutics demonstrated strong performance in key programs, maintained financial stability, and expressed confidence in future prospects.
While facing challenges in device performance and operational planning, the company is well-positioned to capitalize on opportunities for growth and innovation.
Overall, Biora's focus on advancing therapeutic programs and strategic collaborations signals a positive trajectory for the company's future success.

Biora Therapeutics reports stable finances, progresses key drug programs

Biora Therapeutics showcased solid financial management with increased operating expenses but a stable cash position, while also securing additional funding for growth.
The company's focus on key programs and strategic collaborations, coupled with the appointment of a new Chief Medical Officer, bodes well for its clinical development efforts.
Despite challenges in managing expenses and optimizing capital structure, Biora's promising results and strategic initiatives offer opportunities for future growth and success in the pharmaceutical industry.

Biora Therapeutics advances drug delivery platforms and maintains financial stability

Biora Therapeutics showcased progress on innovative drug delivery platforms in Q2 2023. The company's financials remain stable, with a focus on disciplined cash management. Securing partnerships and advancing regulatory filings are key focus areas for future growth.

Biora Therapeutics reduces debt, advances key platforms amid financial challenges

Biora Therapeutics demonstrated financial progress alongside operational advancements in its NaviCap and BioJet platforms, despite facing increased expenses and a net loss for the quarter.
The company's focus on FDA clearance for BT-600 trial initiation and collaborations for the BioJet platform highlights its commitment to advancing innovative therapies and partnerships.
While challenges persist in financial management and collaboration coordination, Biora Therapeutics remains poised to leverage opportunities for growth and market expansion in the biopharmaceutical sector.

Biora Therapeutics excels in Q4 2023 with innovative drug technologies

Biora Therapeutics made significant strides in Q4 2023, advancing their platform technologies and strengthening their financial position. While facing challenges in clinical trials and market competition, the company is well-positioned to capitalize on opportunities for growth and partnerships in the coming year.

Biora Therapeutics advances drug delivery platforms, strengthens financial position

Biora Therapeutics' Q1 performance reflects a strategic focus on R&D, financial strength, and advancements in targeted drug delivery platforms.
The company faces challenges in optimizing partnerships and capital structure while balancing innovation and financial sustainability.
Opportunities lie in upcoming data releases, clinical studies, and partnerships to drive growth and market expansion in 2024.

Biora Therapeutics excels in Q2 with breakthrough drug delivery platforms

Biora Therapeutics' innovative drug delivery platforms show promise in revolutionizing ulcerative colitis treatment and advancing JAK inhibitor therapy.
The company's successful Phase I trial results and capital raise provide a strong foundation for future growth and partnership opportunities.
While challenges lie ahead in scaling up and navigating the competitive landscape, Biora's focus on breakthrough technologies positions them well for success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ambrx Biopharma Inc

Luminar Technologies

Short squeeze stocks to watch. The post Penny Stocks To Buy?

Penny Stocks To Buy? 3 With High Short Interest To Watch This Week

Company is on track to move into the clinic with its lead targeted therapeutics program Company is on track to move into the clinic with its lead targeted therapeutics program

Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023

SAN DIEGO, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will effect a reverse stock split of all outstanding shares of the company's common stock at a ratio of 25 to 1. The company expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Global Market as of the commencement of trading on January 3, 2023.

Biora Therapeutics Announces Reverse Stock Split

SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced acceptance of two abstracts presenting patient data on its targeted therapeutics delivery system for presentation at the Crohn's & Colitis Congress, which will take place January 19-21, 2023, in Denver, Colorado. This annual conference, a partnership of the Crohn's & Colitis Foundation and the American Gastroenterological Association, is focused on bringing together a multidisciplinary community of health care practitioners and researchers to transform inflammatory bowel disease care.

Biora Therapeutics Announces Two Poster Presentations at the Crohn's & Colitis Congress

Avero Diagnostics to Develop and Commercialize, Enabling Potential Future Revenue for Biora Therapeutics Avero Diagnostics to Develop and Commercialize, Enabling Potential Future Revenue for Biora Therapeutics

Biora Therapeutics Licenses Preeclampsia Rule-Out Test for Commercial Development

Biora Therapeutics, Inc. (NASDAQ:BIOR ) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET Company Participants Alexandra Schuman - IR, LifeSci Advisors Adi Mohanty - Chief Executive Officer Eric d'Esparbes - Chief Financial Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Julian Harrison - BTIG Mayank Mamtani - B.

Biora Therapeutics, Inc. (BIOR) Q3 2022 Earnings Call Transcript

Biora Therapeutics, Inc. (BIOR) delivered earnings and revenue surprises of -33.33% and 20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Biora Therapeutics, Inc. (BIOR) Reports Q3 Loss, Misses Revenue Estimates

Presented results of human study at the American College of Gastroenterology annual meeting, demonstrating promising device performance in active ulcerative colitis patients

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report third quarter ended September 30, 2022 financial results on Monday, November 14, 2022 after the close of financial markets. The company's management will host a webcast and conference call at 4:30 PM Eastern time / 1:30 PM Pacific time that day to discuss the financial results and provide a corporate update.

Biora Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update

SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into a definitive agreement with institutional investors for the purchase and sale, in a registered direct offering, of 32,506,250 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 32,506,250 shares of common stock at a combined offering price of $0.30 per share of common stock (or pre-funded warrants in lieu thereof) and accompanying warrant. The warrants have an exercise price of $0.3288 per share, will become exercisable commencing six months following the date of issuance, and will expire five years following the initial exercise date. The closing of the offering is expected to occur on or about November 9, 2022, subject to the satisfaction of customary closing conditions.

Biora Therapeutics Announces $9.75 Million Direct Offering

SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it has completed a one-time asset sale agreement to assign certain patent rights related to methods for determining the origin of cell-free DNA to Roche Diagnostics. Financial terms were not disclosed.

Biora Therapeutics Announces Sale of Cell-Free DNA Patent Rights

Data Presented at the ACG Annual Meeting Demonstrates Successful Detection of Colon Entry and Topical Coverage Throughout Portion of Colon Implicated in Patients with Active Ulcerative Colitis Data Presented at the ACG Annual Meeting Demonstrates Successful Detection of Colon Entry and Topical Coverage Throughout Portion of Colon Implicated in Patients with Active Ulcerative Colitis

Biora Therapeutics Shares Data from Device Performance Study in Ulcerative Colitis Patients

Presents Results on Device Performance Studies in Humans for Targeted Therapeutics Platform Presents Results on Device Performance Studies in Humans for Targeted Therapeutics Platform

Biora Therapeutics Shares Five Posters Presented at American College of Gastroenterology Annual Scientific Meeting 2022

Further Demonstrating Possibilities for Systemic Delivery of Large Molecules Further Demonstrating Possibilities for Systemic Delivery of Large Molecules

Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference

SAN DIEGO, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, announced today that the company will participate in the 12th annual Partnership Opportunities in Drug Delivery (PODD) Conference, October 24-25, 2022 in Boston.

Biora Therapeutics to Participate in 12th Annual Partnership Opportunities in Drug Delivery Conference

Patent Covers Jet Delivery of GLP-1 Receptor Agonists to the Small Intestine for Treatment of Any Disease Including Type 2 Diabetes Patent Covers Jet Delivery of GLP-1 Receptor Agonists to the Small Intestine for Treatment of Any Disease Including Type 2 Diabetes

Biora Therapeutics Announces Issuance of Key Patent for Oral Delivery of GLP-1 Receptor Agonists

SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, announced today the appointment of Dr. Bruce Sands as board chair of its Clinical Advisory Board for Inflammatory Bowel Disease (IBD), which also includes leading IBD researchers Dr. Geert D'Haens, Dr. Brian Feagan, and Dr. Séverine Vermeire. The clinical advisory board provides strategic guidance on clinical development of Biora's Targeted Therapeutics pipeline.

Biora Therapeutics Appoints Dr. Bruce Sands as Chair of its Clinical Advisory Board

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that the company's management team will be presenting and participating in one-on-one meetings at the H.C. Wainwright 24th Annual Global Investment Conference, which is taking place both virtually and at the Lotte New York Palace Hotel in New York City, September 12-14, 2022.

Biora Therapeutics to Participate in Upcoming H.C. Wainwright Investment Conference

Biora Therapeutics, Inc. (NASDAQ:BIOR ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Adi Mohanty – Chief Executive Officer Eric d'Esparbes – Chief Financial Officer Conference Call Participants Julian Harrison – BTIG Yuan Zhi – B. Riley Operator Greetings and welcome to the Biora Therapeutics Second Quarter 2022 Earnings Call.

Biora Therapeutics, Inc's (BIOR) CEO Adi Mohanty on Q2 2022 Results - Earnings Call Transcript

Successfully completed PM-602 human study for its targeted therapeutics platform demonstrating promising device performance in active ulcerative colitis patients

Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

All Devices Successfully Detected Colon Entry in Patients with Active Ulcerative Colitis All Devices Successfully Detected Colon Entry in Patients with Active Ulcerative Colitis

Biora Therapeutics Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for its Targeted Therapeutics Platform

SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that it will report second quarter ended June 30, 2022 financial results on Monday, August 15, 2022 after the close of financial markets. The company's management will host a webcast and conference call at 4:30 PM Eastern time / 1:30 PM Pacific time that day to discuss the financial results and provide a corporate update.

Biora Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update

SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced the acceptance of five abstracts for presentation at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting. ACG's mission is to advance world-class care for patients with gastrointestinal disorders through excellence, innovation, and advocacy in the areas of scientific investigation, education, prevention, and treatment. The 2022 ACG Annual Scientific Meeting will be held in Charlotte, NC and virtually from October 21–26, 2022.

Biora Therapeutics Announces Five Abstracts Accepted at American College of Gastroenterology Annual Scientific Meeting 2022

SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that the company's management team will be participating in one-on-one meetings at the upcoming BTIG Biotechnology Conference, which is taking place both virtually and at the St. Regis New York Hotel in New York City, August 8-9, 2022.

Biora Therapeutics to Participate in Upcoming BTIG Investment Conference

Demonstrates OBDS Device Performance and Bioavailability in Animal Models Demonstrates OBDS Device Performance and Bioavailability in Animal Models

News for Biora Therapeutics Inc Stock (BIOR)